Format
Sort by

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 90

1.

Lack of germ-line promoter methylation in BRCA1-negative families with familial breast cancer.

Chen Y, Toland AE, McLennan J, Fridlyand J, Crawford B, Costello JF, Ziegler JL.

Genet Test. 2006 Winter;10(4):281-4.

PMID:
17253935
2.

Methylation not a frequent "second hit" in tumors with germline BRCA mutations.

Dworkin AM, Spearman AD, Tseng SY, Sweet K, Toland AE.

Fam Cancer. 2009;8(4):339-46. doi: 10.1007/s10689-009-9240-1.

PMID:
19340607
3.

Novel germline mutations in breast cancer susceptibility genes BRCA1, BRCA2 and p53 gene in breast cancer patients from India.

Hedau S, Jain N, Husain SA, Mandal AK, Ray G, Shahid M, Kant R, Gupta V, Shukla NK, Deo SS, Das BC.

Breast Cancer Res Treat. 2004 Nov;88(2):177-86.

PMID:
15564800
4.

Pitfalls and caveats in BRCA sequencing.

Bellosillo B, Tusquets I.

Ultrastruct Pathol. 2006 May-Jun;30(3):229-35. Review.

PMID:
16825125
5.

Childhood cancer in families with and without BRCA1 or BRCA2 mutations ascertained at a high-risk breast cancer clinic.

Brooks GA, Stopfer JE, Erlichman J, Davidson R, Nathanson KL, Domchek SM.

Cancer Biol Ther. 2006 Sep;5(9):1098-102.

PMID:
16931905
6.

Gene promoter hypermethylation in ductal lavage fluid from healthy BRCA gene mutation carriers and mutation-negative controls.

Locke I, Kote-Jarai Z, Fackler MJ, Bancroft E, Osin P, Nerurkar A, Izatt L, Pichert G, Gui GP, Eeles RA.

Breast Cancer Res. 2007;9(1):R20.

7.

Prevalence and type of BRCA mutations in Hispanics undergoing genetic cancer risk assessment in the southwestern United States: a report from the Clinical Cancer Genetics Community Research Network.

Weitzel JN, Clague J, Martir-Negron A, Ogaz R, Herzog J, Ricker C, Jungbluth C, Cina C, Duncan P, Unzeitig G, Saldivar JS, Beattie M, Feldman N, Sand S, Port D, Barragan DI, John EM, Neuhausen SL, Larson GP.

J Clin Oncol. 2013 Jan 10;31(2):210-6. doi: 10.1200/JCO.2011.41.0027. Erratum in: J Clin Oncol. 2013 May 1;31(13):1702.

8.

The frequency of germ-line mutations in the breast cancer predisposition genes BRCA1 and BRCA2 in familial prostate cancer. The Cancer Research Campaign/British Prostate Group United Kingdom Familial Prostate Cancer Study Collaborators.

Gayther SA, de Foy KA, Harrington P, Pharoah P, Dunsmuir WD, Edwards SM, Gillett C, Ardern-Jones A, Dearnaley DP, Easton DF, Ford D, Shearer RJ, Kirby RS, Dowe AL, Kelly J, Stratton MR, Ponder BA, Barnes D, Eeles RA.

Cancer Res. 2000 Aug 15;60(16):4513-8. Erratum in: Cancer Res 2000 Dec 15;60(24):7185.

9.

Promoter methylation patterns of ATM, ATR, BRCA1, BRCA2 and p53 as putative cancer risk modifiers in Jewish BRCA1/BRCA2 mutation carriers.

Kontorovich T, Cohen Y, Nir U, Friedman E.

Breast Cancer Res Treat. 2009 Jul;116(1):195-200. doi: 10.1007/s10549-008-0121-3.

PMID:
18642075
10.

Family history of breast and ovarian cancers and BRCA1 and BRCA2 mutations in a population-based series of early-onset breast cancer.

Loman N, Johannsson O, Kristoffersson U, Olsson H, Borg A.

J Natl Cancer Inst. 2001 Aug 15;93(16):1215-23.

11.

Sex ratio distortion in offspring of families with BRCA1 or BRCA2 mutant alleles: an ascertainment bias phenomenon?

Balmaña J, Díez O, Campos B, Majewski M, Sanz J, Alonso C, Baiget M, Garber JE.

Breast Cancer Res Treat. 2005 Aug;92(3):273-7.

PMID:
16155798
12.

CpG island tumor suppressor promoter methylation in non-BRCA-associated early mammary carcinogenesis.

Vasilatos SN, Broadwater G, Barry WT, Baker JC Jr, Lem S, Dietze EC, Bean GR, Bryson AD, Pilie PG, Goldenberg V, Skaar D, Paisie C, Torres-Hernandez A, Grant TL, Wilke LG, Ibarra-Drendall C, Ostrander JH, D'Amato NC, Zalles C, Jirtle R, Weaver VM, Seewaldt VL.

Cancer Epidemiol Biomarkers Prev. 2009 Mar;18(3):901-14. doi: 10.1158/1055-9965.EPI-08-0875.

13.

Screening for common mutations in BRCA1 and BRCA2 genes: interest in genetic testing of Tunisian families with breast and/or ovarian cancer.

Fourati A, Louchez MM, Fournier J, Gamoudi A, Rahal K, El May MV, El May A, Revillion F, Peyrat JP.

Bull Cancer. 2014 Nov;101(11):E36-40. doi: 10.1684/bdc.2014.2049.

PMID:
25418591
14.

Founder BRCA1 and BRCA2 mutations in Ashkenazi Jews in Israel: frequency and differential penetrance in ovarian cancer and in breast-ovarian cancer families.

Levy-Lahad E, Catane R, Eisenberg S, Kaufman B, Hornreich G, Lishinsky E, Shohat M, Weber BL, Beller U, Lahad A, Halle D.

Am J Hum Genet. 1997 May;60(5):1059-67.

15.

BRCA1 and BRCA2 germline mutation analysis among Indian women from south India: identification of four novel mutations and high-frequency occurrence of 185delAG mutation.

Vaidyanathan K, Lakhotia S, Ravishankar HM, Tabassum U, Mukherjee G, Somasundaram K.

J Biosci. 2009 Sep;34(3):415-22.

16.

Breast cancer risks in women with a family history of breast or ovarian cancer who have tested negative for a BRCA1 or BRCA2 mutation.

Metcalfe KA, Finch A, Poll A, Horsman D, Kim-Sing C, Scott J, Royer R, Sun P, Narod SA.

Br J Cancer. 2009 Jan 27;100(2):421-5. doi: 10.1038/sj.bjc.6604830.

17.
18.

Evaluating the performance of models for predicting the BRCA germline mutations in Han Chinese familial breast cancer patients.

Rao NY, Hu Z, Yu JM, Li WF, Zhang B, Su FX, Wu J, Shen ZZ, Huang W, Shao ZM.

Breast Cancer Res Treat. 2009 Aug;116(3):563-70. doi: 10.1007/s10549-008-0181-4.

PMID:
18807178
19.

BRCA1 and BRCA2 mutation status and tumor characteristics in male breast cancer: a population-based study in Italy.

Ottini L, Masala G, D'Amico C, Mancini B, Saieva C, Aceto G, Gestri D, Vezzosi V, Falchetti M, De Marco M, Paglierani M, Cama A, Bianchi S, Mariani-Costantini R, Palli D.

Cancer Res. 2003 Jan 15;63(2):342-7.

20.

Moderate frequency of BRCA1 and BRCA2 germ-line mutations in Scandinavian familial breast cancer.

Håkansson S, Johannsson O, Johansson U, Sellberg G, Loman N, Gerdes AM, Holmberg E, Dahl N, Pandis N, Kristoffersson U, Olsson H, Borg A.

Am J Hum Genet. 1997 May;60(5):1068-78.

Items per page

Supplemental Content

Support Center